Predictive Oncology Azioni (NASDAQ: POAI)

Ultime notizie per Predictive Oncology (NASDAQ:POAI) Azioni

Predictive Oncology

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Predictive Oncology Inc

Former President Donald Trump has reiterated his commitment to imposing tariffs on cars imported from China and Mexico, aiming to protect American automotive jobs.
What Happened: During an interview with Patrick Bet-David released on Thursday, Trump emphasized the critical role these tariffs would play in safeguarding the U.S. auto industry.
&#8220;I hope the union workers, auto workers understand that I saved their jobs,&#8221; he said.
Trump highlighted a massive car manufacturing plant in Mexico, which he described as potentially one of the largest in the world. He expressed concerns that vehicles from this plant could inundate the U.S. market, leaving little room for American-made cars.
&#8220;That would mean that our car industry is wiped out,&#8221; Trump said.
See Also: <a href="https://www.benzinga.com/news/24/10/41328039/as-elon-musk-unveils-cybercab-uber-ceo-weighs-in-on-robotaxi-competiton-from-waymo-tesla-dont-think?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">As Elon Musk Unveils Cybercab, Uber CEO Weighs In On Robotaxi Competiton From Waymo, Tesla: &#8216;Don&#8217;t Think This Is Going To Be A Winner-Take-All Marketplace&#8217;</a>
Why It Matters: In September, Trump <a href="https://www.benzinga.com/news/24/09/40913456/trump-vows-200-tariffs-on-chinese-made-cars-in-mexico-warns-of-us-auto-industry-collapse-if-kamala-h">proposed a 200% tariff</a> on vehicles produced by alleged Chinese factories in Mexico, as reported in a town hall event in Flint, Michigan. He warned that if Vice President Kamala Harris were elected, the U.S. auto industry could collapse within two to three years due to electric vehicle production shifting to China.
Additionally, during a <a href="https://www.benzinga.com/general/politics/24/10/41279272/donald-trump-pushes-tariffs-on-chinese-cars-in-detroit-visit-vows-to-revamp-industry">visit to the Detroit Economic Club</a> in October, Trump reiterated his commitment to tariffs on Chinese cars, vowing to revamp the industry. He also commented on economic indicators, although some of his statements on inflation and interest rates were inaccurate.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41369986/lucid-stock-is-tumbling-wednesday-whats-driving-the-action?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Lucid Stock Is Tumbling Wednesday: What&#8217;s Driving The Action?</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Wikimedia Commons

News

General

Trump Defends His Plans To Impose 200% Tariffs On Cars Imported From China, Mexico: 'Hope Union Workers Understand That I Saved Their Jobs'

Amid ongoing global economic recovery efforts, Kristalina Georgieva, Managing Director of the International Monetary Fund, has issued a cautionary note regarding persistent challenges such as high debt and low growth. Her remarks come as the U.S. and EU implement rate cuts to tackle inflation.
What Happened: Georgieva highlighted that despite progress, governments are increasingly reliant on borrowing, which, coupled with &#8220;anemic growth,&#8221; complicates debt management. She praised central banks for their inflation control efforts but noted uneven benefits across regions, with some still facing high prices and related unrest, CNBC <a href="https://www.cnbc.com/2024/10/17/imf-chief-warns-low-growth-and-high-debt-weigh-on-global-economy.html">reported</a> on Friday.
"It's not yet time to celebrate," she said.
"When we look into the challenges ahead of us, the biggest one is low growth, high debt. This is where we can and must do better.&#8221;
Georgieva&#8217;s comments precede the 2024 annual meetings of the IMF and World Bank Group in Washington, D.C., where global economic issues will be discussed. She also pointed out that international trade is no longer the &#8220;engine of growth&#8221; it once was, citing restrictive policies and <a href="https://www.benzinga.com/news/24/09/40914629/china-warns-eu-tariffs-on-evs-will-harm-trade-with-germany">U.S.-EU tariffs against China</a> as potential risks. Additionally, she expressed concern over geopolitical tensions, particularly in the Middle East, affecting global financial stability.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41331839/financial-sector-hits-record-highs-as-goldman-sachs-bank-of-america-citi-beat-q3-ea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Financial Sector Hits Record Highs As Goldman Sachs, Bank of America, Citi Beat Q3 Earnings Expectations</a>
Why It Matters: Georgieva&#8217;s comment arrived a day after the European Central Bank (ECB) <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41382372/ecb-slashes-rates-again-will-jerome-powell-take-this-as-cue-for-another-fed-rate-"> cut interest rates</a> for the third time this year to stimulate a sluggish economy, shifting focus from inflation control to economic growth. This move follows the Federal Reserve&#8217;s 50 basis point rate cut in September, marking a significant policy shift as both regions tackle economic challenges.
Meanwhile, the U.S. faces a staggering debt situation, with estimates suggesting a<a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40368118/true-us-debt-is-175-trillion-former-coinbase-cto-on-unpayable-crisis"> true national debt </a>of $175 trillion when accounting for entitlements like Social Security and Medicare. This escalating debt underscores the urgency of addressing fiscal challenges.
In China, the government is reportedly considering issuing $850 billion in<a href="https://www.benzinga.com/markets/asia/24/10/41324527/as-chinas-stimulus-hype-wanes-beijing-reportedly-weighs-850b-special-treasury-bonds-to-stimulate-eco"> special treasury bonds</a> to stimulate its slowing economy and manage local debt. These developments highlight the global nature of economic challenges and the varied approaches being taken to address them.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41372368/mark-cuban-battles-former-trump-advisor-for-suggesting-a-child-could-do-american-auto-workers-job-pa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Battles Former Trump Advisor Over Ex-President&#8217;s Comments On American Auto Workers: &#8216;He Still &nbsp;Thinks It&#8217;s 1965&#8217; (UPDATED)</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Macro Economic Events

Global

Economics

As US Tackles Inflation With Rate Cuts, IMF MD Sounds Alarm: 'Not Yet Time To Celebrate' Amid Looming Low Growth, High Debt

The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) will release earnings results for its first quarter, before the <a href="https://www.benzinga.com/quote/PG/earnings">opening bell on Friday, Oct. 18.</a>
Analysts expect the Cincinnati, Ohio-based bank to report quarterly earnings at $1.90 per share, up from $1.83 per share in the year-ago period. Procter &amp; Gamble projects to report revenue of $21.91 billion for the recent quarter, compared to $19.78 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 30, Procter &amp; Gamble reported fourth-quarter FY24 sales of $20.53 billion (flat Y/Y), missing the analyst consensus estimate of $20.74 billion.
Procter &amp; Gamble shares fell 0.1% to close at $172.28 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5890a92043eaaa0001d69b01/linda-bolton%20weiser">DA Davidson analyst Linda Bolton Weiser</a> maintained a Neutral rating with a price target of $159 on Oct. 15. This analyst has an accuracy rate of 61%.</li>
<li>Barclays analyst Lauren Lieberman downgraded the stock from Overweight to Equal-Weight with a price target of $163 on Sept. 30. This analyst has an accuracy rate of 63%.</li>
<li>JP Morgan analyst Andrea Teixeira maintained an Overweight rating and increased the price target from $179 to $186 on Sept. 19. This analyst has an accuracy rate of 61%.</li>
<li>TD Cowen analyst Robert Moskow initiated coverage on the stock with a Buy rating and a price target of $189 on July 23. This analyst has an accuracy rate of 65%.</li>
<li>Stifel analyst Mark Astrachan maintained a Hold rating and raised the price target from $157 to $161 on July 22. This analyst has an accuracy rate of 78%.</li>
</ul>
Considering buying PG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="482" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-1024x482.png" alt="" class="wp-image-602127" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-1024x482.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-300x141.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158.png 1365w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

Earnings

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Procter & Gamble Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans,Benson &amp; Hedges Inc. (RBH), that the court-appointed mediator and monitor in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding filed a proposed plan of compromise and arrangement (Proposed Plan) outlining certain terms of a comprehensive resolution of tobacco product-related claims and litigation in Canada against RBH and its affiliates. The court-appointed mediator and monitors also filed substantially similar proposed plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM).
Under the Proposed Plan, if ultimately approved and implemented, RBH, ITL and JTIM (the Companies) would pay an aggregate settlement amount of CAD 32.5 billion (approximately USD 23.5 billion). This amount would be funded by an upfront payment equal to the Companies' cash and cash equivalents on hand in Canada plus certain court deposits (subject to an aggregate withholding of CAD 750 million (approximately USD 540 million) for working capital inclusive of cash pledged as collateral) and annual payments based on a percentage of the Companies' net income after taxes (excluding that generated by certain non-combustible products including heat-not-burn, e-vapor and nicotine pouch products) until the aggregate settlement amount is paid. As stated in the Proposed Plan, the issue of allocation of the CAD 32.5 billion aggregate settlement as between the Companies in the CCAA proceedings remains unresolved.
"After years of mediation, we welcome this important step towards the resolution of long-pending tobacco product-related litigation in Canada," said Jacek Olczak, Chief Executive Officer of PMI. "Although important issues with the plan remain to be resolved, we are hopeful that this legal process will soon conclude, allowing RBH and its stakeholders to focus on the future."

Legal

Philip Morris, Imperial Tobacco, JTI-Macdonald Face $23.5B Settlement in Canada Tobacco Lawsuits

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cloudflare.com%2F&amp;esheet=54138023&amp;newsitemid=20241018840279&amp;lan=en-US&amp;anchor=Cloudflare%2C+Inc.&amp;index=1&amp;md5=3e1a02702fd6e8744473a752dd19c5f5">Cloudflare, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), the leading connectivity cloud company, today announced the opening of a new headquarters and technical hub in Lisbon, Portugal to further support its growing EMEA operations and offices in London, Paris, Munich, and Dubai. Portugal already represents a growing Cloudflare team.
Today, Cloudflare's network currently spans 58 cities in Europe, including Lisbon, Portugal, which was announced in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fblog.cloudflare.com%2Famsterdam-to-zhuzhou-cloudflare-global-network%2F&amp;esheet=54138023&amp;newsitemid=20241018840279&amp;lan=en-US&amp;anchor=2016&amp;index=2&amp;md5=89c437ed99560575fd137ba7cd354fa5">2016</a>. Cloudflare announced its first office in Lisbon in 2019. Since establishing an office in the region, the company has grown from 14 employees to more than 350 in Portugal. Cloudflare plans to significantly increase its presence in Lisbon over the coming years.
Cloudflare celebrated the official opening of its new office with a ribbon cutting ceremony, followed by a reception attended by Portugal's Minister of Economy, Mr. Pedro Reis, along with other Portuguese officials. Top Cloudflare executives were also in attendance, including Cloudflare co-founder and CEO Matthew Prince, and John Graham-Cumming, CTO &amp; Head of the Lisbon office, which he opened in July 2019.

Government

Regulations

Cloudflare Expands European Operations With New Lisbon Headquarters, Plans Major Workforce Growth

Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) will release earnings results for its third quarter, before the<a href="https://www.benzinga.com/quote/SLB/earnings"> opening bell on Friday, Oct. 18.</a>
Analysts expect the Buffalo, New York-based company to report quarterly earnings at 88 cents per share, up from 71 cents per share in the year-ago period. SLB projects to report revenue of $9.25 billion for the quarter, compared to $7.58 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Thursday, SLB agreed to sell its interests in Palliser Block.
SLB shares gained 0.7% to close at $43.99 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SLB/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580874cb846faa000106ac9d/david-anderson">Barclays analyst David Anderson</a> maintained an Overweight rating and cut the price target from $67 to $63 on Oct. 16. This analyst has an accuracy rate of 63%.</li>
<li>Stifel analyst Stephen Gengaro maintained a Buy rating and cut the price target from $65 to $62 on Oct. 11. This analyst has an accuracy rate of 60%.</li>
<li>BMO Capital analyst Philip Jungwirth maintained an Outperform rating and cut the price target from $60 to $58 on Oct. 10. This analyst has an accuracy rate of 61%.</li>
<li>JP Morgan analyst Arun Jayaram maintained an Overweight and cut the price target from $64 to $60 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li>Morgan Stanley analyst Connor Lynagh maintained an Overweight rating and slashed the price target from $65 to $60 on Sept. 16. This analyst has an accuracy rate of 60%.</li>
</ul>
Considering buying SLB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="511" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-1024x511.png" alt="" class="wp-image-602108" style="width:705px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-1024x511.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-768x383.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157.png 1338w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

SLB Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled mostly higher on Thursday, with the Dow Jones index climbing to a new record close following the release of economic data.
U.S. initial jobless claims fell by 19,000 in the week ending Oct. 12. U.S. retail sales rose 0.4% month-over-month in September compared to a 0.1% increase in August and higher than market estimates of a 0.3% rise. The Philadelphia Fed Manufacturing Index climbed to 10.3 in October compared to 1.7 in September and topping market estimates of 3.
Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) shares jumped around 9.8% on Thursday following better-than-expected third-quarter earnings and strong fourth-quarter guidance
Most sectors on the S&amp;P 500 closed on a negative note, with utilities, communication services, and real estate stocks recording the biggest losses on Thursday. However, energy and information technology stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed higher by around 161 points to 43,239.05 on Thursday. The S&amp;P 500 slipped 0.02% to 5,841.47, while the Nasdaq Composite rose 0.04% at 18,373.61 during Thursday's session.
Investors are awaiting earnings results from American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), and Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 71.5, the index remained in the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 69.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>
Photo courtesy: Shutterstock

TSMC, Strong Economic Data Push Dow To Fresh Record High: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) to report quarterly earnings at $3.28 per share on revenue of $16.67 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. American Express shares gained 1.8% to $290.91 in after-hours trading.</li>
<li>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected third-quarter financial results, posting revenue of $9.825 billion, up 15% year-over-year, versus market estimates of $9.769 billion. The company ended the third quarter with 282.72 million global paid subscribers, up 14.4% year-over-year. Netflix shares climbed 5.1% to $722.35 in the after-hours trading session.</li>
<li>Analysts are expecting The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) to post quarterly earnings at $1.90 per share on revenue of $21.91 billion. The company will release earnings before the markets open. Procter &amp; Gamble shares gained 0.1% to $172.50 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) posted better-than-expected third-quarter financial results. The company also said it obtained regulatory clearance in South Korea for the da Vinci 5 surgical system in October. Intuitive Surgical shares climbed 6.1% to $502.80 in the after-hours trading session.</li>
<li>Analysts expect Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) to report quarterly earnings at 88 cents per share on revenue of $9.25 billion before the opening bell. SLB shares rose 0.4% to $44.16 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>
Photo courtesy: Shutterstock

ISRG

NFLX

Netflix, American Express And 3 Stocks To Watch Heading Into Friday

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) founder Michael Saylor encouraged those who doubt the upside potential of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to go short on the company's stock, assuring that it would never sell the cryptocurrency.
What happened: During an interview with journalist Madison Reidy that aired Thursday, Saylor asked skeptics to "love" MicroStrategy if they really "hate" Bitcoin.
"We&#8217;re the perfect instrument to short because I promise you, I won&#8217;t sell it. We&#8217;re going to be leveraged long on Bitcoin," said Saylor, one of the most passionate advocates of the cryptocurrency.
&#8220;I want you to love us if you really hate BTC.&#8221;
Saylor said as a company, MicroStrategy has been consistent and transparent in its policy of buying and holding on to Bitcoin, and it was up to market participants to decide if they wanted to buy, sell, or short their shares.
"When I was a younger man I would have been concerned about people shorting my stock but now I&#8217;m not," Saylor added.&nbsp;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41373332/donald-trump-backed-world-liberty-financial-off-to-a-slow-start-raises-just-4-of-the-token">Donald Trump-Backed World Liberty Financial Off To A Slow Start — Raises Just 4% Of The Token Fundraising Target</a>
Why It Matters: Saylor&#8217;s remarks came amid MicroStratgy&#8217;s audacious Bitcoin gambit, which has transformed the software development firm into a proxy for the world&#8217;s greatest digital asset.
MicroStrategy <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40306998/since-embracing-bitcoin-4-years-ago-michael-saylors-microstrategy-has-outperformed-warren-">adopted Bitcoin as its primary reserve asset</a> in 2020, becoming the first publicly listed company to pursue this strategy, and hasn't looked back since then. Today, it holds over $17 billion of its total capital in Bitcoin, <a href="https://bitcointreasuries.net/">according</a> to bitcointreasuries.net.
Saylor projects that by 2045, <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40916462/michael-saylor-bitcoin-to-hit-13m-by-2045-will-get-us-to-a-different-place#:~:text=Michael%20Saylor%3A%20Bitcoin%20To%20Hit,To%20A%20Different%20Place'%20%2D%20Benzinga">Bitcoin will constitute 7% of global financial capital</a>, implying a $13 million price per Bitcoin.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Michael Saylor: Why MicroStrategy's Bitcoin funding is NOT a glitch" width="500" height="281" src="https://www.youtube.com/embed/eThjo9wYoF0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Price Action: At the time of writing, Bitcoin was exchanging hands at $67,931.57, up 0.98% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Shares of MicroStrategy closed down 0.35% to $193.42 during Thursday's regular trading session.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41372654/peter-schiff-questions-trump-inspired-bitcoin-pump-one-of-the-promises-he-did-not-make-was">Peter Schiff Question &#8216;Trump-Inspired&#8217; Bitcoin Pump: &#8216;One Of The Promises He Did Not Make Was To Buy Any&#8217;</a></li>
</ul>
Photo courtesy: Wikimedia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy Boss Michael Saylor Taunts Bitcoin Doubters, Challenges Them To Short Company's Stock: 'I Want You To Love Us If You Really Hate BTC'

Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary Waymo is providing riders who <a href="https://www.benzinga.com/news/24/06/39494723/waymo-autonomous-rides-now-available-to-everyone-in-san-francisco-heres-how-you-can-enjoy-driverless">avail an autonomous ride</a> to select transit stations in San Francisco and the Peninsula $3 credit in a bid to promote public transportation, the company said on Thursday.
What Happened: Waymo will credit $3 to riders&#8217; accounts if they take an autonomous ride to or from eligible Bay Area transit stations. These credits can be used for future rides.
The program started on Oct. 17 and will go on till Nov.15. The credits can be used until Dec. 31, according to a statement from Waymo. 
&#8220;By offering electric rides on demand and improving access to public transit, Waymo One is making daily travel more sustainable and convenient,&#8221; said Adam Lenz, Head of Sustainability and Environment at Waymo.
Why It Matters: Waymo currently operates a fleet of all-electric vehicles that have been customized to enable autonomous driving. The company is delivering over 100,000 paid autonomous rides every week to the public, the company said on Thursday.
Automotive research firm&nbsp;S&amp;P Global Mobility&nbsp;said in September that it deems&nbsp;<a href="https://www.benzinga.com/news/24/09/40792410/us-autonomous-vehicle-sales-to-hit-230k-by-2034-after-progress-resumes-at-alphabets-waymo-gms-cruise" target="_blank" rel="noreferrer noopener">Waymo to be the frontrunner&nbsp;</a>in the field of autonomous vehicles in the U.S.&nbsp;
&nbsp;In July, Alphabet committed&nbsp;to a new multiyear&nbsp;<a href="https://www.benzinga.com/news/24/07/39924838/alphabet-commits-to-another-5b-investment-in-waymo-tesla-ceo-elon-musk-takes-jibe-at-cash-burn-in-un" target="_blank" rel="noreferrer noopener">investment of $5 billion into Waymo</a>&nbsp;to help the company "continue to build the world's leading autonomous driving technology company."
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41324450/elon-musk-says-spacexs-next-generation-starlink-satellites-will-be-so-big-that-only-starship-can-lau" target="_blank" rel="noreferrer noopener">Elon Musk Says SpaceX&#8217;s Next-Generation Starlink Satellites Will Be ‘So Big That Only Starship Can Launch Them:&#8217; Will Offer 10X Increase In Bandwidth And Reduced Latency</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

GOOG

GOOGL

Waymo Offers Free Credits To Riders Traveling To Select Transit Stations In The Bay Area: Here's How Much You Can Get

Coca-Cola Europacific Partners plc (&quot;CCEP&quot; or the &quot;Company&quot;) today confirms notification of transfer of UK listing category from the Equity Shares (Transition) category to the Equity Shares (Commercial Companies) category of the Official List

Coca-Cola European Partners plc Ordinary Shares

CCEP

Coca-Cola Europacific Partners To Shifts To Commercial Companies Category, Paving The Way For FTSE Index Eligibility

NYCB

Reported Earlier, Flagstar Bank, Subsidiary of New York Community Bancorp, Cuts 8% of Workforce In Strategic Transformation And Cost-Cutting Initiative

Lotus continues to achieve top-rate growth among traditional luxury car brands, delivering 7,543 vehicles1&nbsp;in the first nine months of 2024, representing a year-on-year increase of&nbsp;134%. Global allocation in terms of deliveries remained well-distributed, with Europe, China, North America and the Rest of the World regions each contributing about&nbsp;20-35%&nbsp;of the total deliveries. In the&nbsp;third quarter&nbsp;of 2024, Emeya (GT, Sedan) was delivered to Europe, whilst Eletre (SUV) reached markets including the GCC, Japan and Korea.

Reported Earlier, Lotus Technology Reports 134% YoY Vehicle Delivery Surge In First Nine Months Of 2024

Econ #s

U.K. Retail Sales (YoY) For September 3.9% Vs. 3.2% Est.; 2.3% (Revised) Prior

U.K. Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.0% Prior

U.K. Core Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.1% Prior

U.K. Core Retail Sales (YoY) For September 4.0% Vs. 3.2% Est.; 2.2% (Revised) Prior

Netflix Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) Co-CEO&nbsp;Ted Sarandos on Thursday outlined why the streaming giant continues to hold an edge over YouTube, a subsidiary of Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google.
What Happened: During Netflix&#8217;s <a href="https://www.benzinga.com/news/earnings/24/10/41391637/netflix-q3-earnings-revenue-beats-eps-tops-q4-guidance-projects-subscriber-boost-from-squid-game-nf">third-quarter earnings</a> call, a question about&nbsp;YouTube&#8217;s growing share of TV&nbsp;consumption was raised.
In response, Sarandos highlighted Netflix&#8217;s commitment to investing in premium content to increase viewer engagement, stating, &#8220;Netflix is the best place&nbsp;for premium stories because we&#8217;re&nbsp;the home to the best&nbsp;storytellers.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/10/41375934/meta-confirms-layoffs-across-instagram-whatsapp-and-reality-labs-amid-strategic-reshuffle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Meta Confirms Layoffs Across Instagram, WhatsApp And Reality Labs Amid Strategic Reshuffle</a>
Regarding YouTube, he said, &#8220;When I look at YouTube specifically, I&#8217;d say look, we compete directly with YouTube for people&#8217;s time, for the time they spend on that TV screen. But we have very different strengths.&#8221;
Another, Netflix Co-CEO Greg Peters added that Netflix plays a crucial role for consumers seeking high-quality movies and TV shows, and for creators looking for partners willing to share the inherent risks of bringing stories to life.
&#8220;A Hundred Years of Solitude, Senna, both coming from Latin America, which are huge, ambitious projects. It&#8217;s hard to imagine how those kind of big creative bets would be possible with YouTube&#8217;s model,&#8221; Peters stated.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Netflix&#8217;s third-quarter financial results showed a 15% year-over-year increase in revenue, beating Street consensus estimates.
Moreover, Netflix&#8217;s recent foray into live sports programming indicates a strategic shift from its traditional on-demand model. This move aims to capture high-impact moments and the <a href="https://www.benzinga.com/general/entertainment/24/10/41395213/netflixs-200b-hour-problem-why-live-sports-are-just-a-drop-in-the-streaming-ocean">excitement of global live events</a>, further enhancing viewer engagement.
During the <a href="https://www.benzinga.com/news/earnings/24/07/39849026/netflix-q2-earnings-highlights-revenue-beat-eps-beat-advertising-revenue-more-meaningful-squid-game" target="_blank" rel="noreferrer noopener">second-quarter earnings</a> call, Netflix executives were asked questions about YouTube.
At the time, Sarandos&nbsp;said, &#8220;So our two services — us and YouTube represent about 50% of all streaming to the TV in the U.S. and we use the U.S. only because that's where we have the data.&#8221;
&#8220;So really what we're focused on here is focusing ourselves on that other 80% of total TV time that isn't going to either us or YouTube,&#8221; he said in July.
Sarandos <a href="https://www.benzinga.com/general/entertainment/24/07/39853498/netflix-aims-to-capture-broader-tv-market-sees-youtube-as-both-competitor-and-partner-we-ki">reiterated Netflix&#8217;s commitment to focus</a> on the remaining 80% of the market during the third-quarter call too.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41356479/apple-spark-hope-for-americas-semiconductor-comeback-key-supplier-tsmc-reportedly-begins-producing-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Spark Hope For America&#8217;s Semiconductor Comeback: Key Supplier TSMC Reportedly Begins Producing Chips In US For iPhone Maker</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Unsplash

Entertainment

Equities

Netflix's Ted Sarandos Downplays Concerns Of YouTube's Growing Share Of TV Consumption: 'We're The Home To The Best Storytellers'

Orders and deliveries
In Q3, net order intake decreased by 8% to 43,234 trucks and deliveries decreased by 16% to 46,266 units. Deliveries of heavyduty trucks decreased by 9%, of medium-duty trucks by 21% and of light-duty trucks by 61%.

VLVLY

Volvo's Q3 Saw 8% Drop In Net Order Intake To 43,234 Trucks, With Deliveries Down 16% To 46,266 Units

Volvo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VLVLY#OTC">VLVLY</a>) reported quarterly earnings of $0.47 per share. This is a 26.18 percent decrease over earnings of $0.64 per share from the same period last year. The company reported $11.22 billion in sales this quarter. This is a 8.38 percent decrease over sales of $12.25 billion the same period last year

VLVCY

Volvo Q3 EPS $0.47 Down From $0.64 YoY, Sales $11.22B Down From $12.25B YoY

Predictive Oncology, Augmedix, Cue Health among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
When does a growth stock become one of the top <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a> to avoid?



It sounds like the beginning of a riddle or a bad joke, but the answer is obvious &ndash; it&rsquo;s when the stock is deceptive and tricks you into believing that it can be a good buy. You look at the Portfolio Grader and get interested because a stock has a good grade specifically for growth, but then realize that it still has an &ldquo;F&rdquo; rating overall.



How can that happen?



The Portfolio Grader rates stocks based on earnings history, growth, analyst sentiment and momentum. The growth grade in particular is a popular metric for finding growth stocks to avoid.



But it&rsquo;s also important to see why a company is getting a good growth grade. Because sometimes, looking at a single factor like growth can be misleading and can&rsquo;t make up for the company&rsquo;s deficiencies in other areas.



Today, we&rsquo;re going to look at several companies that have good growth grades, and we&rsquo;ll investigate why that&rsquo;s happening in each case. But then we&rsquo;ll pull back the curtain, look at the fuller picture, and explore why these growth stocks to avoid are still getting &ldquo;F&rdquo; grades overall.



In the end, an exercise like this is a good reminder to not rely on any one metric when considering your stock portfolio. Growth is highly desirable, but the growth stocks to avoid on this list can easily drag your portfolio into the gutter.



<h2>Virgin Galactic (SPCE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/spce1600-300x169.jpg" alt="Virgin Galactic (SPCE) billboard on the New York Stock Exchange, across from the Fearless Girl statue. aerospace stocks"><div>Source: Tun Pichitanon / Shutterstock.com</div></div>It makes sense to jump right into one of the growth stocks to avoid that&rsquo;s been a huge disappointment &ndash; and has cost plenty of investors a lot of money along the way. 



Virgin Galactic (NYSE:<a href="https://investorplace.com/stock-quotes/spce-stock-quote/">SPCE</a>) made its name in the billionaire space race as founder Richard Branson competed with SpaceX and Blue Orgin to see which would be the first to make it into space with a civilian crew. 



You may remember that Virgin Galactic won that race, as it shot Branson into suborbital flight just a few days before Jeff Bezos did the same on a Blue Orgin rocket.



But honestly, that&rsquo;s the high point for this company. Space tourism doesn&rsquo;t feel any closer today than it did several years ago, and few people have the several hundred thousand dollars it takes to make the trip, even if the flights become a reality.



Virgin Galactic has burned through more than $1 billion in the last two years and rewarded investors with a 93% fall in stock price. SPCE recently completed a <a href="https://investorplace.com/2024/06/will-a-1-for-20-reverse-split-save-virgin-galactic-spce-stock/">1-for-20 reverse stock split</a> to push the price back over the Nasdaq threshold and maintain listing compliance, but the reality is that this is a bad stock and a weak company.



SPCE stock shows an &ldquo;A&rdquo; rating for growth in the Portfolio Grader because its revenue was up 410% in the last quarter. But sales of only $1.99 million show that people aren&rsquo;t lining up to ride a <a href="https://seekingalpha.com/article/4690417-virgin-galactic-holdings-inc-spce-q1-2024-earnings-call-transcript?source=content_type%3Areact%7Csection%3ATranscripts%7Csection_asset%3ATranscripts%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A2">Delta rocket</a> into space as early as 2026, which is the company&rsquo;s latest projections.



SPCE stock gets an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Helius Medical Technologies (HSDT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/tech1600a-300x169.jpg" alt="Image of hand touching globe with a city in the background, implying connectivity"><div>Source: Shutterstock</div></div>Helius Medical Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) is a neurotech company headquartered in eastern Pennsylvania. The company makes medical devices that help people with balance and gait issues without getting a neurological implant. It is also one of the growth stocks to avoid in the space.



The company&rsquo;s devices improve the brain&rsquo;s ability to compensate for deficiencies and rehabilitate lost brain function. For instance, its Portable Neuromodulation Stimulator stimulates the brain through nerves in the tongue. 



It&rsquo;s being used as a short-term treatment to help people with multiple sclerosis symptoms. But it&rsquo;s an expensive device, priced at more than $23,000.



The company saw <a href="https://ir.heliusmedical.com/news-releases/news-release-details/helius-medical-technologies-inc-reports-first-quarter-2024">revenue grow</a> in the first quarter, giving it a decent growth grade in the Portfolio Grader. But we&rsquo;re still not looking at a lot of money. Revenue in the first quarter was $135,000, versus $111,000 in the same quarter a year ago.



It posted a net loss of $2.5 million, the same as a year ago. The earnings per share loss of $3.08 was better than the loss of $4.22 per share from Q1 2023.



HSDT stock is down 87% this year. It has an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>InMed Pharmaceuticals (INM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-1-1-300x169.jpg" alt="cannabis stocks"><div>Source: Shutterstock</div></div>InMed Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/inm-stock-quote/">INM</a>) is a Canadian company that is a clinical-stage pharmaceutical company that&rsquo;s working to develop cannabis-infused treatments for Alzheimer&rsquo;s disease, vision and skin conditions.



The company is attempting to develop an effective pipeline of drug candidates targeting CB1 and CB2 receptors. 



Its attempt to develop an anti-itch skin cream is in Phase 2 testing, and it is seeking a partnership to help it develop the product. Its other pipeline candidates for Alzheimer&rsquo;s and dry age-related macular degeneration are in preclinical trials.



Developing new therapies is an expensive undertaking and a challenge for investors because the company has to spend a lot of cash on research and development without seeing income for years, if ever.



For the third fiscal quarter of 2024 (ending March 31), InMed reported a net loss of $5.7 million. The company saw sales of $1.1 million, up slightly from a year ago, and a gross profit of $289,000, which was better than its profit of $192,511 in the same quarter a year ago.



The profit increase helps InMed&rsquo;s growth grade in the Portfolio Grader. Still, the company also acknowledges that it has money only to finance research and development into the fourth calendar quarter of 2024. That is a worrisome disclosure.



INM stock gets a &ldquo;B&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader. The stock is down 36% this year.



<h2>P3 Health Partners (PIII)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600a-300x169.jpg" alt="stethoscope on a stock chart representing healthcare stocks to buy. Healthcare Stocks"><div>Source: Shutterstock</div></div>P3 Health Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/piii-stock-quote/">PIII</a>) is a health management company that supports providers with administrative services and coordination for their Medicare Advantage patients.



The company currently operates in Arizona, Oregon, Nevada, Florida and California, with a network of more than 2,900 primary care providers.



It recently announced raising <a href="https://ir.p3hp.org/news-events/press-releases/detail/106/p3-health-partners-inc-announces-approximately-42-2">$42.2 million</a> through the sale of 67.4 million units of stock with institutional investors, valued at just over 62 cents per share. That will give the company an infusion of cash to operate, but it also serves to dilute the share base.



First-quarter financial results included $388.5 million in revenue, up 29% from a year ago. But gross profits fell from $16.5 million to $6.4 million, and the company reported a net loss of $49.6 million.



PIII is among the growth stocks to avoid in part because it is down 62% this year. It gets an &ldquo;A&rdquo; rating for growth, but still has an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Sunshine Biopharma (SBFM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) is a Florida-based biopharma company developing potential treatments in oncology and antivirals.



Thanks to its ownership of a Canadian pharmacy, Nora Pharma, which distributes generic medications, Sunshine was able to show <a href="https://sunshinebiopharma.com/wp-content/uploads/20240521_SBFM-Press-Release-Reports-Q1_2024_.pdf">sales</a> of $7.5 million in the first quarter, a gain from $4.8 million a year ago. That gives it a solid grade for growth in the Portfolio Grader.



However, Sunshine is a long path to ever bringing its own drugs to market, and that&rsquo;s where the real money is made. Sunshine is currently testing a Covid-19 treatment in mice at the University of Arizona in hopes of developing a treatment for patients who cannot use Paxlovid, Molnupiravir or Remdisivir.



It has a second drug candidate, to treat cancer, ready for testing on mice as well. However, the company&rsquo;s third drug candidate, also a cancer drug, is on hold after lab tests did not yield a favorable result.



The Nora Pharma sales weren&rsquo;t enough to help Sunshine generate a profit for the quarter, either. It posted a net loss of $1.2 million versus a loss of $1.7 million in the first quarter of 2023.



SBFM stock is down 98% this year. It gets an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>MicroVision (MVIS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/06/mvis1600-300x169.png" alt="Autonomous Self Driving Car Moving Through highway - Animated Scanning Visualization Concept of Artificial Intelligence Digitalizes and Analyzes Road Using Lidar. MVIS stock"><div>Source: aslysun / Shutterstock.com</div></div>With more vehicles on the road these days than ever, the advances in driver-assisted technology are pretty interesting. MicroVision (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvis-stock-quote/">MVIS</a>) makes automotive lidar sensors to help driver-assistance systems and autonomous vehicles function.



The company&rsquo;s sensors are also used in industrial, smart infrastructure and robotics.



It gets a good grade for growth in the Portfolio Grader because the company increased its revenue in the first quarter, bringing in $956,000 versus $782,000 in the first quarter of 2023. That&rsquo;s a healthy percentage increase that helps give it an &ldquo;A&rdquo; grade for growth.



But then look closer. MicroVision lost <a href="https://ir.microvision.com/news/press-releases/detail/402/microvision-announces-first-quarter-2024-results">$26.3 million in the quarter</a>, versus a loss of $19 million in the same quarter a year ago. When you&rsquo;re losing that much money, an $174,000 increase in revenue doesn&rsquo;t help that much.



MVIS stock is down 59% this year. Despite its &ldquo;A&rdquo; grade for growth, MicroVision gets an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Predictive Oncology (POAI)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/02/artificial-intelligence-ai-brain-tech-1600-768x432-1.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/artificial-intelligence-ai-brain-tech-1600-768x432-1-300x169.jpg" alt="A concept image representing AI (artificial intelligence)."></a>Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) is working to harness the power of artificial intelligence to help bring drugs to market. The company believes that AI can help reduce the time it takes to successfully test and manufacture a drug, and is working specifically on cancer therapies.



The company has a biobank of&nbsp;<a href="https://predictive-oncology.com/biobankai/">150,000 tumor tissue samples</a>&nbsp;and uses machine learning to help it test and discover successful molecules. It also uses AI for drug development and for clinical trials.



And it saw an uptick in revenue in the first quarter, bringing in $419,000 versus $239,000 in the first quarter of 2023.



But the company also posted a loss of $4.2 million and $1.04 per share, versus a loss of $3.4 million and 86 cents per share in the same quarter a year ago.



That&rsquo;s why POAI stock is getting an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader. The stock is down 67% this year.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-f-rated-growth-stocks-to-avoid-right-now-june-2024/">7 F-Rated Growth Stocks to Avoid Right Now: June 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 F-Rated Growth Stocks to Avoid Right Now: June 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Shares of biotechnology specialist Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) &mdash; which leverages artificial intelligence (AI) and machine learning models for the discovery of novel biomarkers in cancer research protocols &mdash; soared on Thursday. Earlier, the company announced a major development in terms of the predictability models of ovarian cancer. Therefore, POAI stock jumped higher on the credibility boost.



According to the biotech firm&rsquo;s <a href="https://finance.yahoo.com/news/predictive-oncology-enters-biomarker-discovery-110000330.html">press release</a>, a retrospective ovarian cancer study with UPMC Magee-Womens Hospital (based in Pittsburgh, Pennsylvania) demonstrated that Predictive&rsquo;s ML models can more accurately forecast short-term and long-term survival outcomes compared to clinical data alone.



Fundamentally, this development has brought much excitement to POAI stock because Predictive&rsquo;s deep learning protocol &mdash; combined with a diverse biobank of patient samples &mdash; may help accelerate biomarker discovery tied to patient survival and therapeutic response.



In addition, the underlying technology can act as a force multiplier, advancing the development of clinical support tools. The innovation may also allow for more efficient screening for clinical trial enrollment.



<h2>Massive Addressable Market Bodes Well for POAI Stock</h2>



Beyond the clinical implications, POAI stock soared on the underlying massive total addressable market. According to the release, the biomarker discovery market may end up with a valuation of $51.5 billion by year&rsquo;s end. Right now, the market capitalization of Predictive sits at $7.14 million.



Further, the sector might only expand from here on out. Data from Grand View Research states that the global biomarker ecosystem was already worth $81.04 billion last year. Whatever the case, experts project that the industry could expand at a <a href="https://www.grandviewresearch.com/industry-analysis/biomarkers-industry">compound annual growth rate of 13.36%</a> by 2030. By the forecast culmination point, it may be worth $194.21 billion.



Again, with POAI stock featuring just a morsel of the growing pie, the opportunity for speculators is immense. Still, it must also be acknowledged that Predictive represents a highly speculative investment.



Since the start of the year, POAI stock dropped more than 50% in value. That&rsquo;s inclusive of today&rsquo;s blistering run. Further, in the past 52 weeks, POAI suffered a drop of 64%. Not surprisingly, Wall Street analysts currently do not cover Predictive Oncology. Still, that might change due to the equity&rsquo;s strong performance and significant credibility boost.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-predictive-oncology-poai-stock-up-70-today/">Why Is Predictive Oncology (POAI) Stock Up 70% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Predictive Oncology (POAI) Stock Up 70% Today?

Predictive Oncology looks to raise $1.3M through exercise of warrants

Here's the major earnings before the open tomorrow

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) just reported results for the second quarter of 2024.<ul><li>Predictive Oncology reported earnings per share of -68 cents.</li><li>The company reported revenue of $278,722.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/poai-stock-earnings-predictive-oncology-for-q2-of-2024/">POAI Stock Earnings: Predictive Oncology Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

POAI Stock Earnings: Predictive Oncology Reported Results for Q2 2024

Predictive Oncology GAAP EPS of -$0.68, revenue of $0.28M

Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript

Predictive Oncology files to sell 1.98M shares of common stock for holders

Predictive Oncology (POAI – Research Report) received a Buy rating and a $3.00 price target from H.C. Wainwright analyst Swayampakula Ramakanth tod...

H.C. Wainwright Initiates a Buy Rating on Predictive Oncology (POAI)

ALHC

ARCO

AUGX

BCLI

BKKT

BLUE

BSGM

CRMD

DOLE

EONGY

ESLT

FLNG

GANX

GLBE

HLTH

HNHAF

HSDT

IMNN

IPWR

ITRM

KMDA

KPLT

MDWD

MEDIF

MGIC

MVIS

ONDS

ONMD

OTLK

PFGC

PIII

POAI

PRPH

RSKD

SACH

SBFM

SGHT

SPCE

SUNS

TCEHY

TSAT

VISL

VWDRY

WKHS

Health Care

Press Releases

Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024

Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)

Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results

Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds

Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

Predictive Oncology Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development

Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update

Predictive Oncology Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery

Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HC Wainwright & Co.

Comments

Predictive Oncology

Notizie

Ultime notizie per Predictive Oncology (NASDAQ:POAI) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO